Ruxolitinib

Red

Brand Name(s):Jakavi

Indication:Graft versus host disease (GvHD) Acute and Chronic.

Myelofibrosis – Chronic idiopathic myelofibrosis and treatment of myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia

Rationale:1,2

Considered:May-12

Review Date:Jan-26

Comments:
Rapid policy statement: Ruxolitinib for acute graft versus host disease

Rapid policy statement: Ruxolitinib for chronic Graft versus Host Disease

NICE TA 386
March 2016